How critical is the part therapeutics in the COVID-19 pandemic? – podcast

2 March 2021
Posted in Covid-19, Editor's Choice, News | Tagged , , ,

The latest DDW Sitting Down With podcast features Guy Goldberg, Chief Business Officer of RedHill Biopharma.

RedHill Biopharma  is a biopharmaceutical company that recently announced the dosing of the first patient in its US Phase II/III study of orally-administered RHB-107 (upamostat), an investigational new drug for patients with symptomatic COVID-19 who do not require hospital care.

Goldberg talks us through Covid-19 therapeutics and their role in the pandemic.

Listen now to share in his market insight, expertise on developing Covid-19 therapies, the benefits of an orally-administered small molecule tablet for COVID treatment and how the company has achieved and maintained its success in the therapeutics market.

Listen here.

 

 

 

 

 

 

 

 

 

 

 

 

 

Suggested Reading

Combination treatment for AML closer to approval following EMA nod
23 August 2022
Stressed scientist Researchers worried about public scrutiny after the pandemic
9 November 2022

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free